Osteoporosis Drugs Sales

Osteoporosis Drugs Sales Market Outlook

The global osteoporosis drugs market is anticipated to reach approximately USD 18.2 billion by 2035, growing at a compound annual growth rate (CAGR) of around 6.7% during the forecast period from 2025 to 2035. The increasing prevalence of osteoporosis, particularly among the aging population, and the rising awareness regarding bone health are major growth factors driving this market. Furthermore, advancements in drug formulations and therapies, along with the growing emphasis on preventive healthcare measures, are expected to bolster market growth significantly. The aging population, coupled with lifestyle changes leading to increased risk factors such as sedentary lifestyles and nutritional deficiencies, is also contributing to the rising incidences of osteoporosis. Additionally, the expansion of healthcare infrastructure, improved access to medications, and innovative treatment options are expected to fuel the market demand for osteoporosis drugs.

Growth Factor of the Market

One of the primary growth factors for the osteoporosis drugs market is the expanding elderly population worldwide. As the global population ages, the incidence of osteoporosis and related fractures is anticipated to rise, necessitating the need for effective treatment options. Moreover, advancements in pharmaceutical research and development are leading to the introduction of novel drugs with enhanced efficacy and safety profiles, which are instrumental in driving market growth. Increased healthcare expenditure and the rising prevalence of risk factors such as obesity, smoking, and physical inactivity are further contributing to the demand for osteoporosis medications. The growing emphasis on preventive care and early diagnosis is also significant, as more individuals are seeking treatment options before experiencing severe complications. Additionally, government initiatives and awareness campaigns aimed at educating the public about osteoporosis management are expected to foster market growth.

Key Highlights of the Market

• The global osteoporosis drugs market is projected to grow at a CAGR of 6.7% from 2025 to 2035.
• Bisphosphonates are expected to hold a significant share of the market due to their wide acceptance and efficacy.
• Injectable forms of osteoporosis drugs are gaining traction due to their convenience and effectiveness.
• North America is anticipated to dominate the market owing to advanced healthcare systems and higher awareness levels.
• The introduction of new drug formulations and combination therapies is expected to enhance treatment outcomes.

By Drug Type

Bisphosphonates:

Bisphosphonates are one of the most widely prescribed classes of drugs for osteoporosis management, primarily due to their established efficacy in reducing fracture risk. This drug type works by inhibiting osteoclast-mediated bone resorption, thereby improving bone density and structural integrity. Common bisphosphonates include alendronate, risedronate, and zoledronic acid. They are known for their oral and intravenous formulations, which provide physicians with flexible treatment options based on patient needs. The favorable clinical outcomes associated with bisphosphonates, combined with extensive clinical evidence supporting their long-term safety profile, make them a preferred choice among healthcare providers. The ongoing research to improve patient adherence with once-yearly intravenous administration is further expected to drive their market growth.

Parathyroid Hormone Therapy:

Parathyroid hormone therapy is another effective treatment option for osteoporosis, particularly for patients at high risk of fractures. This therapy involves the administration of synthetic parathyroid hormone, which stimulates bone formation and enhances bone density. Teriparatide is the most commonly used parathyroid hormone analog, and it is generally administered via daily subcutaneous injections. The unique mechanism of action of parathyroid hormone therapy distinguishes it from other osteoporosis treatments, as it actively promotes bone growth rather than merely preventing bone loss. Despite its higher cost compared to other therapies, its ability to significantly reduce fracture risk makes it an attractive option for patients with severe osteoporosis. Continuous advancements in formulations and delivery methods are anticipated to enhance patient compliance and expand the adoption of parathyroid hormone therapy in clinical practice.

Selective Estrogen Receptor Modulators:

Selective estrogen receptor modulators (SERMs) represent a crucial segment in the osteoporosis drugs market, particularly for women undergoing menopause. This class of drugs, which includes raloxifene, mimics the effects of estrogen on bone tissue, thereby reducing bone resorption and minimizing the risk of fractures. SERMs are especially valuable for postmenopausal women, as estrogen loss is a primary risk factor for osteoporosis. The dual mechanism of action, which also provides a protective effect against breast cancer, makes SERMs a preferred option for certain patient populations. However, the market growth potential for SERMs is influenced by their side effects and the availability of alternative therapies that may offer greater efficacy and safety. Continuous research into novel SERMs with improved profiles is expected to revitalize interest and utilization in this segment.

Calcitonin:

Calcitonin is a hormone that plays a significant role in calcium regulation and bone metabolism, and has been utilized in the treatment of osteoporosis, particularly in postmenopausal women. It works by inhibiting osteoclast activity, which consequently reduces bone resorption. Calcitonin is available in both nasal spray and injectable forms, offering patients flexibility in administration. While its use has declined in recent years due to the emergence of more effective osteoporosis treatments, calcitonin continues to be a valuable option for patients who may not tolerate bisphosphonates or other therapies. The market for calcitonin is expected to be stable, with niche use cases driving demand. Ongoing studies to elucidate its long-term benefits and potential in combination therapies could revive interest in calcitonin within the osteoporosis treatment landscape.

RANK Ligand Inhibitors:

RANK ligand inhibitors, such as denosumab, represent an innovative approach to osteoporosis treatment by targeting the receptor activator of nuclear factor-kappa B (RANK) pathway, which is crucial for osteoclast formation and function. By inhibiting RANK ligand, denosumab effectively reduces bone resorption and increases bone mass. Denosumab is delivered via subcutaneous injection every six months, making it a convenient option for patients. Its efficacy in reducing fracture risk in both men and women, along with its unique mechanism of action, positions RANK ligand inhibitors as a significant segment of the osteoporosis drugs market. As awareness grows regarding the benefits of long-term use and the management of potential side effects, the adoption of RANK ligand inhibitors is expected to increase, contributing positively to market growth.

By Route of Administration

Oral:

Oral administration remains the most common route for osteoporosis drugs, primarily due to its convenience and ease of use for patients. Many first-line therapies, such as bisphosphonates, are available in oral formulations, making it easier for patients to adhere to their treatment regimens. Oral medications are preferred by a significant portion of the population, especially older adults who may be averse to injections. The oral route allows for flexibility in dosing schedules, contributing to better patient compliance. However, challenges such as gastrointestinal side effects and the need for specific administration protocols can impact patient adherence. As formulators continue to innovate and introduce user-friendly oral medications, this segment is expected to maintain its dominance in the osteoporosis drugs market.

Injectable:

Injectable osteoporosis medications are gaining popularity due to their efficacy and the potential for enhanced patient compliance. This route of administration is particularly beneficial for patients who experience gastrointestinal issues with oral medications or those who require a more aggressive treatment approach. Injectable therapies, including parathyroid hormone and RANK ligand inhibitors, often provide more immediate effects on bone density and fracture risk. The introduction of long-acting injectable formulations that require less frequent dosing, such as biannual injections, addresses adherence issues commonly faced with daily or weekly oral therapies. As healthcare providers increasingly recognize the advantages of injectable treatments in managing osteoporosis, this segment is poised for significant growth in the coming years.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a critical role in the distribution of osteoporosis drugs, particularly within inpatient settings and specialized clinics. These pharmacies often provide comprehensive medication management and personalized care for patients with complex medical histories, ensuring they receive appropriate therapies. Hospital pharmacies typically stock a wide range of osteoporosis medications, including injectable therapies, which are essential for acute care and immediate treatment needs. The collaboration between healthcare providers and hospital pharmacists enhances treatment outcomes by ensuring proper medication counseling and adherence monitoring. As healthcare systems increasingly focus on integrated care models, the significance of hospital pharmacies in the osteoporosis treatment landscape is expected to grow further.

Retail Pharmacies:

Retail pharmacies serve as a vital distribution channel for osteoporosis drugs, offering patients easy access to medications within their communities. This channel provides a wide selection of oral osteoporosis therapies, which are often the first line of treatment for many patients. The convenience of retail pharmacy locations and extended hours can significantly improve medication adherence, as patients can easily obtain their prescriptions. In addition, retail pharmacies often engage in patient education initiatives, helping individuals understand their treatment options and the importance of adherence. The growing trend of pharmaceutical companies partnering with retail pharmacies to offer promotional campaigns and patient support programs is expected to drive market growth within this segment.

Online Pharmacies:

The emergence of online pharmacies has transformed the way patients access osteoporosis medications by providing a convenient and discreet option for obtaining prescriptions. Online pharmacies offer a wide range of drugs, often at competitive prices, which can enhance patient access, particularly for those who may face challenges visiting traditional pharmacy settings. The increased acceptance of telehealth services has further bolstered the growth of online pharmacies, allowing patients to receive consultations and prescriptions from healthcare professionals remotely. Despite regulatory challenges and concerns regarding the legitimacy of some online vendors, the convenience and accessibility provided by this distribution channel are expected to drive its growth in the osteoporosis drugs market. As consumer confidence in online pharmacies continues to rise, this segment is poised for significant expansion.

By End User

Hospitals:

Hospitals are one of the primary end users of osteoporosis drugs, as they cater to patients requiring immediate and comprehensive care for osteoporosis-related complications. Inpatient settings provide a vital platform for the diagnosis, treatment, and management of osteoporosis, particularly in cases of fractures and other acute conditions. Hospitals benefit from access to a range of osteoporosis medications, including injectable therapies that are often necessary for patients with severe osteoporosis. The collaborative approach of multidisciplinary teams within hospitals ensures that patients receive optimal pharmacological interventions along with necessary rehabilitation services. As hospitals increasingly adopt integrated care models that emphasize the management of chronic conditions such as osteoporosis, their role as end users of osteoporosis drugs is projected to grow significantly.

Clinics:

Specialty clinics focused on osteoporosis care represent a key end-user segment for osteoporosis drugs, providing targeted treatment and management options for patients. These clinics are often staffed by healthcare professionals who specialize in bone health, allowing for personalized treatment plans that consider individual risk factors and medical histories. Clinics typically offer a range of osteoporosis medications, including both oral and injectable options, to meet the diverse needs of their patient populations. The focus on preventive care and patient education within these settings is crucial in promoting adherence to prescribed therapies. As public awareness of osteoporosis continues to rise, specialty clinics are expected to grow in prominence as centers of excellence for osteoporosis management and drug utilization.

Homecare:

Homecare services are becoming increasingly relevant in the osteoporosis drugs market as more patients seek treatment options that allow them to manage their health from the comfort of their homes. The rise of home healthcare reflects a broader trend toward patient-centered care models that prioritize convenience and accessibility. Homecare providers often facilitate the administration of injectable osteoporosis medications, helping patients overcome barriers related to self-injection. Additionally, these services can provide education and support for medication adherence, dietary recommendations, and lifestyle modifications that promote bone health. The growing aging population and the shift towards home-based healthcare solutions are expected to significantly drive the demand for osteoporosis drugs in the homecare segment.

By Region

North America is anticipated to dominate the osteoporosis drugs market, accounting for approximately 40% of the global market share by 2035. The region's strong economic position, advanced healthcare infrastructure, and a high prevalence of osteoporosis among the aging population contribute to its leading status. Furthermore, the presence of key pharmaceutical companies engaged in the research and development of innovative osteoporosis treatments drives market growth. The CAGR for the North American osteoporosis drugs market is projected to be around 7.2% during the forecast period, reflecting the growing demand for effective therapies. The increasing awareness of bone health, along with enhanced access to treatment options, is expected to reinforce North America's dominant position in the market.

Europe is another significant region in the osteoporosis drugs market, expected to hold approximately 30% of the market share by 2035. The region benefits from a well-established healthcare system and a growing elderly population, which is driving the demand for osteoporosis medications. Countries such as Germany, France, and the UK are witnessing a rise in osteoporosis awareness campaigns, contributing to increased diagnosis and treatment rates. The European osteoporosis drugs market is projected to grow at a CAGR of 6% during the forecast period, driven by the introduction of new treatment options and the expansion of reimbursement policies that support patient access to medications. Additionally, ongoing collaboration between governments and healthcare organizations to address the growing burden of osteoporosis is anticipated to enhance market growth prospects in Europe.

Opportunities

The osteoporosis drugs market presents numerous opportunities for growth and innovation, particularly with the advent of advanced drug formulations and novel therapeutic approaches. The ongoing research into combination therapies that synergistically enhance treatment outcomes is one such opportunity, as these treatments may offer improved efficacy while reducing the risk of adverse effects. Additionally, the development of personalized medicine approaches that tailor treatment plans based on individual patient profiles could significantly enhance patient adherence and outcomes. The increasing focus on preventive healthcare measures also offers substantial growth potential, as healthcare providers seek to educate patients about osteoporosis risk factors and the importance of early intervention. Furthermore, as telehealth services expand, the ability to reach underserved populations with osteoporosis management solutions can open new market avenues and improve overall patient access to care.

Moreover, the rising incidence of osteoporosis in developing regions presents an untapped market opportunity for pharmaceutical companies. As awareness of osteoporosis increases in these regions, there is a growing demand for effective treatment options. Companies that can establish a strong presence in emerging markets by leveraging local partnerships and adapting their marketing strategies can capture significant market share. The potential for innovative delivery systems, such as long-acting injectables or alternative administration routes, further enhances the attractiveness of entering these markets. As the global emphasis on healthcare accessibility continues to rise, opportunities for growth within the osteoporosis drugs market are expected to expand considerably over the coming years.

Threats

Despite the promising growth prospects within the osteoporosis drugs market, several threats could hinder progress. One significant concern is the increasing competition from generic medications, which can lead to price erosion and reduced profit margins for branded products. As patents for many osteoporosis drugs expire, the influx of generic alternatives may challenge the market share of established companies. Additionally, the rising prevalence of counterfeit medications poses a serious threat to patient safety and brand integrity, particularly in regions with less stringent regulatory oversight. This issue can undermine consumer confidence in legitimate products and negatively affect market dynamics. Furthermore, the ongoing regulatory changes and evolving reimbursement policies across various markets could introduce uncertainty for pharmaceutical companies, impacting their ability to launch new products or maintain market access.

Moreover, there are potential restraining factors that could limit the growth of the osteoporosis drugs market. One major concern is the side effects associated with certain osteoporosis medications, which may deter patients from adhering to treatment regimens. For instance, gastrointestinal issues linked to oral bisphosphonates or the risk of osteonecrosis of the jaw associated with long-term use of bisphosphonates can lead to hesitancy among patients. Additionally, the lack of awareness regarding osteoporosis prevention and treatment in some populations may further impede market growth. Comprehensive educational initiatives aimed at both healthcare professionals and patients are essential to address these gaps and ensure timely diagnosis and effective management of osteoporosis. Without proactive efforts to combat these threats and restraining factors, the market could face challenges in achieving its full growth potential.

Competitor Outlook

• Amgen Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Horizon Therapeutics plc
• UCB S.A.
• AbbVie Inc.
• Gilead Sciences, Inc.
• Roche Holding AG
• Eli Lilly and Company
• Sun Pharmaceutical Industries Ltd.
• Ferring Pharmaceuticals Inc.

The competitive landscape of the osteoporosis drugs market is characterized by the presence of several key players, each striving to innovate and expand their market share. Established pharmaceutical companies continue to invest in research and development to create novel therapies that offer enhanced efficacy and safety profiles. This competitive environment is fueled by the growing demand for effective osteoporosis treatments, particularly as the population ages and the prevalence of osteoporosis rises. Major players are focusing on strategic collaborations, mergers, and acquisitions to enhance their product portfolios and expand their geographic reach. Additionally, the emphasis on personalized medicine and patient-centric approaches is driving companies to explore new avenues for treatment, creating opportunities for differentiation in this competitive marketplace.

Companies like Amgen Inc. and Merck & Co., Inc. are at the forefront of osteoporosis drug development, with a strong focus on innovative therapies. Amgen's Prolia (denosumab) and Merck's Fosamax (alendronate) are prime examples of successful products that have made significant impacts in the market. Amgen has also been actively involved in research to explore the potential of combination therapies that leverage the strengths of existing treatments, while Merck emphasizes patient education and support programs to enhance adherence to their medications. Both companies are engaged in ongoing clinical trials aimed at exploring new indications and improving the understanding of long-term treatment effects.

In addition, Novartis AG and Pfizer Inc. are notable competitors in the osteoporosis drugs market, with a commitment to advancing treatment options for patients. Novartis's Zometa (zoledronic acid) is widely used for its efficacy in preventing skeletal-related events in patients with bone metastases, while Pfizer's Forteo (teriparatide) plays a crucial role in stimulating bone growth. Both companies have been proactive in addressing patient needs through education, adherence programs, and innovative delivery options. Furthermore, their investment in clinical research and development ensures that they remain competitive in a rapidly evolving market landscape. As these companies continue to innovate and adapt to changing market dynamics, their contributions will shape the future of osteoporosis treatment.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 UCB S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Eli Lilly and Company
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Gilead Sciences, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Horizon Therapeutics plc
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Ferring Pharmaceuticals Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Osteoporosis Drugs Sales Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Homecare
  • 6.2 Osteoporosis Drugs Sales Market, By Drug Type
    • 6.2.1 Bisphosphonates
    • 6.2.2 Parathyroid Hormone Therapy
    • 6.2.3 Selective Estrogen Receptor Modulators
    • 6.2.4 Calcitonin
    • 6.2.5 RANK Ligand Inhibitors
  • 6.3 Osteoporosis Drugs Sales Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies
  • 6.4 Osteoporosis Drugs Sales Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Injectable

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Osteoporosis Drugs Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Osteoporosis Drugs Sales market is categorized based on

By Drug Type

• Bisphosphonates
• Parathyroid Hormone Therapy
• Selective Estrogen Receptor Modulators
• Calcitonin
• RANK Ligand Inhibitors

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User

• Hospitals
• Clinics
• Homecare

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Amgen Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Horizon Therapeutics plc
• UCB S.A.
• AbbVie Inc.
• Gilead Sciences, Inc.
• Roche Holding AG
• Eli Lilly and Company
• Sun Pharmaceutical Industries Ltd.
• Ferring Pharmaceuticals Inc.